Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 15;16(3):e0248571.
doi: 10.1371/journal.pone.0248571. eCollection 2021.

Psoriatic arthritis screening: A systematic literature review and experts' recommendations

Ana Urruticoechea-Arana  1 , Diego Benavent  2 , Fernando León  3 , Raquel Almodovar  4 , Isabel Belinchón  5 , Pablo de la Cueva  6 , Cristina Fernández-Carballido  7 , Estíbaliz Loza  8 , Jordi Gratacós  9 ; Cribado Working Group
Affiliations

Psoriatic arthritis screening: A systematic literature review and experts' recommendations

Ana Urruticoechea-Arana et al. PLoS One. .

Abstract

Objective: To analyze the performance of psoriatic arthritis (PsA) screening tools, examine their implementation in daily practice, and reach a consensus about the best screening tool for implementation in daily practice in different medical settings.

Methods: A systematic literature review (SLR), structured telephone interviews to hospitals, and a multidisciplinary nominal group meeting were all conducted. The SLR employed sensitive search strategies using Medline, Embase, and the Cochrane Library up to January 2020. Two reviewers independently selected articles that reported data on PsA screening tools and that included sufficient data to at least calculate the sensitivity and specificity of those tools (e.g., questionnaires, algorithms, specific questions, and biomarkers). The hospital interviews collected data regarding the process of suspected PsA diagnosis and referral to rheumatology, the implementation of PsA screening tools, and barriers and facilitators to implementation of those tools. In the nominal group meeting, a multidisciplinary team of experts discussed all these data and subsequently recommended a screening tool for implementation.

Results: The SLR included 41 moderate-quality studies that analyzed 14 PsA screening tools, most of which were questionnaire-based tools. All of these studies reported a moderate-good performance but presented different characteristics regarding the time to completion or the number and type of items or questions. The implementation of screening tools was low (30.5%). The experts ultimately recommended regular use of a PsA screening tool, preferably the PURE-4 questionnaire.

Conclusions: The implementation of PsA screening tools like the PURE-4 questionnaire in daily practice likely improves the prognosis of PsA patients.

PubMed Disclaimer

Conflict of interest statement

The authors have read the journal’s policy and have the following competing interests: IB acted as a consultant and/or speaker for and/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including Janssen Pharmaceuticals Inc, Almirall SA, Lilly, AbbVie, Novartis, Celgene, Amgen, Leo-Pharma, Pfizer-Wyeth, UCB, and MSD; EL has received research grants from Roche, AbbVie, Novartis, Amgen, Leo-Pharma, Pfizer-Wyeth, UCB, Astellas, BMS, Sanofi and MSD but these research grants received by EL are not associated with this study; DB received grants/speaker/research supports from Roche, Novartis and Abbvie but these grants and support received by DB are not associated with this study; PDC acted as consultant, advisory board member, honorary for speaking and participation in clinical trials with the following pharmaceutical companies: Abbvie, Almirall, Astellas, Biogen, Boehringer, Celgene, Janssen, LEO Pharma, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi, UCB, and did not receive any funding, including in the form of salary, for this study from mentioned entities. FL has received honoraria from Novartis. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There are no patents, products in development or marketed products associated with this research to declare.

Figures

Fig 1
Fig 1. Studies flow-chart.
See this image and copyright information in PMC

References

    1. Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al.. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251–65 e19. 10.1016/j.jaad.2018.06.027 - DOI - PubMed
    1. Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273–84. 10.1016/S0140-6736(18)30830-4 - DOI - PubMed
    1. Christophers E, Barker JN, Griffiths CE, Dauden E, Milligan G, Molta C, et al.. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol. 2010;24(5):548–54. 10.1111/j.1468-3083.2009.03463.x - DOI - PubMed
    1. Villani AP, Rouzaud M, Sevrain M, Barnetche T, Paul C, Richard MA, et al.. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis. J Am Acad Dermatol. 2015;73(2):242–8. 10.1016/j.jaad.2015.05.001 - DOI - PubMed
    1. Spelman L, Su JC, Fernandez-Penas P, Varigos GA, Cooper AJ, Baker CS, et al.. Frequency of undiagnosed psoriatic arthritis among psoriasis patients in Australian dermatology practice. J Eur Acad Dermatol Venereol. 2015;29(11):2184–91. 10.1111/jdv.13210 - DOI - PubMed

Publication types